Article Data

  • Views 751
  • Dowloads 159

Original Research

Open Access

Incidence, mortality and survival analyses for carcinosarcoma from 1975 to 2018: an epidemiological study

  • Lin Liu1,†
  • Yaqing Zhu2,†
  • Cuiling Zhou3,4,†
  • Yun Tian1,*,

1Zhaoqing Medical College, 526020 Zhaoqing, Guangdong, China

2Department of General Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, 441000 Xiangyang, Hubei, China

3Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, 441000 Xiangyang, Hubei, China

4Institute of Oncology, Hubei University of Arts and Science, 441021 Xiangyang, Hubei, China

DOI: 10.22514/ejgo.2024.028 Vol.45,Issue 2,April 2024 pp.60-65

Submitted: 04 September 2022 Accepted: 10 November 2022

Published: 15 April 2024

*Corresponding Author(s): Yun Tian E-mail:

† These authors contributed equally.


Carcinosarcoma (CS) is a rare malignant tumor, with little known about its epidemiological features in literature. This study aimed to report the largest and latest analysis on the incidence, mortality and survival of CS. Data of CS from the Surveillance, Epidemiology and End Results (SEER) database (SEER-9 incidence database and SEER-9 incidence-based mortality database) were retrieved and assessed. Incidence, mortality and survival analyses were performed using the SEER*Stat software. We used annual percentage change (APC) to evaluate the trends in incidence and mortality. The results showed that the incidence rate of CS increased from 0.36/100,000 to 0.83/100,000, with an APC of 3.4%, from 1975 to 2018. Its mortality rate followed a similar pattern, with an APC increase of 3.2% from 0.07/100,000 in 1975 to 0.54/100,000 in 2018. Most CS cases were reported to be from the female genital system. The 5-year survival rate of all patients was 34.9%. CS is an aggressive tumor with increasing incidence and mortality trends. This tumor, especially CS in the female genital system, should no longer be considered a rare tumor. This research broads our knowledge of CS and provides important insights for clinicians.


Carcinosarcoma; Epidemiology; Incidence; Mortality; Survival

Cite and Share

Lin Liu,Yaqing Zhu,Cuiling Zhou,Yun Tian. Incidence, mortality and survival analyses for carcinosarcoma from 1975 to 2018: an epidemiological study. European Journal of Gynaecological Oncology. 2024. 45(2);60-65.


[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Virchow R. Die krankhaften Geschwülste. 1st ed. Springer: Berlin. 1863.

[3] Wick MR, Swanson PE. Carcinosarcomas: current perspectives and an historical review of nosological concepts. Seminars in Diagnostic Pathology. 1993; 10: 118–127.

[4] Lin S, Liu C, Tao Z, Zhang J, Hu X. Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: a SEER population-based study. Breast. 2020; 49: 157–164.

[5] Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecologic Oncology. 2013; 131: 46–51.

[6] Pang A, Carbini M, Moreira AL, Maki RG. Carcinosarcomas and related cancers: tumors caught in the act of epithelial-mesenchymal transition. Journal of Clinical Oncology. 2018; 36: 210–216.

[7] Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecologic Oncology. 1997; 65: 158–163.

[8] Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. International Journal of Gynecological Cancer. 2014; 24: S55–60.

[9] Qian ZJ, Jin MC, Meister KD, Megwalu UC. Pediatric thyroid cancer incidence and mortality trends in the United States, 1973–2013. JAMA Otolaryngology—Head & Neck Surgery. 2019; 145: 617.

[10] Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013; 119: 1149–1158.

[11] Lewis DR, Siembida EJ, Seibel NL, Smith AW, Mariotto AB. Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975–2016. Cancer. 2021; 127: 4277–4286.

[12] Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. Journal of the National Cancer Institute. Monographs. 2014; 2014: 145–186.

[13] McCluggage WG, McManus DT, Lioe TF, Hill CM. Uterine carcinosarcoma in association with tamoxifen therapy. British Journal of Obstetrics and Gynaecology. 1997; 104: 748–750.

[14] Palda VA, Goel V, Sawka CA. The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario. Breast Cancer Research and Treatment. 1997; 43: 33–41.

[15] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022; 72: 7–33.

[16] Matsuo K, Ross MS, Machida H, Blake EA, Roman LD. Trends of uterine carcinosarcoma in the United States. Journal of Gynecologic Oncology. 2018; 29: e22.

[17] Ersek JL, Symanowski JT, Han Y, Howard A, Dumas K, Ahrens W, et al. Pulmonary carcinosarcoma: a surveillance, epidemiology, and end results (SEER) analysis. Clinical Lung Cancer. 2020; 21: 160–170.

[18] Argüelles Salido E, Travado Soria P, Pérez Espejo MP, Rodríguez Corchero J, Medina López RA, Pena Outeiriño JM. Carcinosarcoma of the bladder: report of our cases and review of the literature. Actas Urologicas Españolas. 2004; 28: 262–268. (In Spanish)

[19] Marco FD, Piombino E, Portale TR, Magro G, Pesce A. Carcinosarcoma of the stomach: a rare tumor for an unusual localization. Review of the literature. Turkish Journal of Gastroenterology. 2019; 30: 1066–1069.

[20] Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97: 934–959.

[21] Wu SG, Chen XT, Zhang WW, Sun JY, Li FY, He ZY, et al. Survival in signet ring cell carcinoma varies based on primary tumor location: a surveillance, epidemiology, and end results database analysis. Expert Review of Gastroenterology & Hepatology. 2018; 12: 209–214.

[22] Bonazzi VF, Kondrashova O, Smith D, Nones K, Sengal AT, Ju R, et al. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. Genome Medicine. 2022; 14: 3.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time